Business Wire

APPEN

7.3.2019 17:02:08 CET | Business Wire | Press release

Share
Appen 1,000+ Seat Facility in the Philippines Achieves ISO 27001 Accreditation for Secure Collection and Annotation of AI Datasets

Appen Limited today announced the achievement of ISO/IEC 27001:2013 accreditation for its facility in Cavite, Philippines to meet the rapidly growing demand for human-annotated datasets used by companies worldwide to train machine learning and artificial intelligence (AI) applications.

The facility was established to ensure commercial confidentiality and better support privacy management. Globally recognized, the ISO/IEC 27001:2013 standard defines the requirements for an Information Security Management System (ISMS), and a process-based approach for establishing, implementing, operating, monitoring, maintaining and improving the ISMS.

ISO/IEC 27001:2013 accreditation underpins Appen’s ability to work on datasets for clients that contain personally identifiable information – data that could potentially identify a specific individual – as well as other sensitive material, such as data related to new product development.

“Appen’s facility in the Philippines gives clients enhanced options to scale their AI programs with the assurance that their sensitive data and projects will remain secure,” said Mark Brayan, Appen’s chief executive officer. “It’s the perfect complement to our high-security facility in the U.K., and is an important part of our suite of secure at-home and in-facility solutions.”

Appen works with the world’s leading technology companies, as well as firms across all industries to provide high-quality data for their machine learning programs. Appen’s suite of secure solutions includes secure facilities as well as secure remote worker options designed to scale customers’ machine learning programs while maintaining data privacy. Use case examples range from voice recognition in smart speakers to geospatial analysis in self-driving cars, to intelligent search and online advertising results.

Industry analysts estimate the data collection and annotation market will be worth up to $19 billion – approximately 10% of the overall AI market – by 2025. The explosive growth is attributed to the need for high volumes of annotated data that are required to improve AI algorithm accuracy. Today, approximately one-third of AI applications require frequent or monthly data updates, and one-quarter of those need weekly updates, according to McKinsey Global Institute.

Datasets created by Appen include image, text, audio, video and relevance data, as well as speech and natural language data from over 130 countries and more than 180 languages and dialects.

The announcement today follows Appen’s recent reporting of record results of AU$364.3 million in 2018, representing 119% growth year-over-year.

During the company shareholder call last week, Brayan outlined Appen’s 2019 growth initiatives that include increasing technology development to improve the productivity of its global crowd of over 1 million skilled contractors who develop the AI training datasets in conjunction with Appen’s Client Services team. In addition to expanding Appen’s secure solutions, the company also plans to increase its full-time staff and investments in China, the largest AI market outside of the U.S.

Founded in 1996, Appen has office locations worldwide including Seattle, San Francisco, Detroit, and Beijing in addition to the Philippines, U.K. and its headquarters in Sydney.

About Appen

Appen is a global leader in the development of high-quality, human-annotated datasets for machine learning and artificial intelligence. Appen brings over 20 years of experience capturing and enriching a wide variety of data types including speech, text, image, and video. With deep expertise in more than 180 languages and access to a global crowd of over 1 million skilled contractors, Appen partners with technology, automotive and e-commerce companies — as well as governments worldwide — to help them develop, enhance and use products that rely on natural languages and machine learning.

Contact:

Jodie Ruby VP of Marketing jruby@appen.com 425-442-8014

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye